Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems

Haemophilia

Volumn 14, Issue 5, 2008, Pages 956-962

  Burnouf, Thierry ^a,e   Caron, C ^b   Radosevich, M ^a   Goubran, H A ^c   Goudemand, J ^b   El ekiaby, M ^d  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b Center Hospitalier et Universitaire   (France)

^c CAIRO UNIVERSITY   (Egypt)

^d Shabrawishi Hospital Blood Bank   (Egypt)

^e NONE   (France)

Author keywords

Cryoprecipitate; Factor VIII; Fibrinogen; Minipool; Solvent detergent; Virus; Von Willebrand factor

Indexed keywords

AGGLUTININ; BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE; COLLAGEN; DETERGENT; FIBRINOGEN; GLUCOSE; RISTOCETIN; SODIUM CHLORIDE; SOLVENT; VON WILLEBRAND FACTOR;

ANTIBODY TITER; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG SYNTHESIS; PRIORITY JOURNAL; VIRUS INACTIVATION;

EID: 51249116440     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01797.x     Document Type: Article

References (30)

1. Srivastava A. Factor replacement therapy in haemophilia - are there models for developing countries? Haemophilia 2003; 9: 391-6.
2. Srivastava A. Factor replacement for haemophilia - should cryoprecipitate be used? Haemophilia 1999; 5: 301-5.
3. Farrugia A, Giangrande P. Choice of replacement therapy for hemophilia-cryoprecipitate issues: A rebuttal. J Thromb Haemost 2004; 2: 1022-3.
4. Kasper CK. Products for clotting factor replacement in developing countries. Semin Thromb Hemost 2005; 31: 507-12.
5. Hoffman M, Koepke JA, Widmann FK. Fibrinogen content of low-volume cryoprecipitate. Transfusion 1987; 27: 356-8.
6. Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA 1979; 241: 1690-1.
7. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92: 846-9.
8. Marshall S. Commercial fibrinogen, autogenous plasma, whole blood and cryoprecipitate for coagulum pyelolithotomy: A comparative study. J Urol 1978; 119: 310-401.
9. Blood supply and demand. Lancet 2005; 365: 2151.
10. Evatt B, Austin H, Leon G, Ruiz-Saez A, de Bosch N. Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate. Haemophilia 2000; 6: 128-32.
11. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 2006; 91: 56-62.
12. Burnouf T, Goubran H, Radosevich M, El-Ekiaby M. Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries. ISBT Sci Ser 2007; 2: 121-8.
13. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-40.
14. Burnouf T, Caron C, Burkhardt T, Goudemand J. Content and functional activity of von Willebrand factor in apheresis plasma. Vox Sang 2004; 87: 27-33.
15. Eby C, Chance D, Oliver D. A multicenter evaluation of STA-LIATEST VWF: a new latex particle immunoassay for von Willebrand factor antigen. Clin Hemost Rev 1997; 11: 16-7.
16. Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2: 285-91.
17. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-3.
18. Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemost 1986; 55: 61-4.
19. Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997; 78: 930-3.
20. Turecek PL, Siekmann J, Schwarz HP. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor. Semin Thromb Hemost 2002; 28: 149-60.
21. Menache D, Aronson DL. New treatments of von Willebrand disease: Plasma derived von Willebrand factor concentrates. Thromb Haemost 1997; 78: 566-70.
22. Favaloro EJ, Bukuya M, Martinelli T et al. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates. Thromb Haemost 2002; 87: 466-76.
23. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology 1997; 29: 385-91.
24. Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94: 756-8.
25. Keeling DM, Luddington R, Allain JP, Lawrie AS, Williamson LM. Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol 1997; 96: 194-7.
26. Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004; 86: 100-4.
27. Mannucci PM. Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease. Haemostasis 1994; 24: 285-8.
28. Fricke WA, Yu MY. Characterization of von Willebrand factor in factor VIII concentrates. Am J Hematol 1989; 31: 41-5.
29. Federici AB, Mannucci PM. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia 1998; 4: 7-10.
30. Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: A survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 7: 235-41.